In patients with moderate to severe atopic dermatitis, nemolizumab demonstrated good durability of response, explained Jonathan Silverberg, MD, PhD, MPH, FAAD, of George Washington University School of Medicine and Health Sciences.
This content was produced independently by The American Journal of Managed Care® and is not endorsed by the American Academy of Dermatology.
The results of this study demonstrated good durability of response and even some ongoing improvement with nemolizumab beyond week 16 up to week 48 in patients with moderate to severe atopic dermatitis (AD), says Jonathan Silverberg, MD, PhD, MPH, FAAD, professor of dermatology, director of clinical research and patch testing, George Washington University School of Medicine and Health Sciences.
Transcript
Can you provide an overview of the study and the primary efficacy end points achieved at week 48 in both ARCADIA-1 and ARCADIA-2 studies for patients with moderate to severe AD receiving nemolizumab?
The late-breaking presentation was for data from ARCADIA-1 and ARCADIA-2. These are 2 global, phase 3 randomized control trials that included both adolescents and adults with moderate to severe atopic dermatitis. And the primary efficacy end points and readouts were presented a few months ago at the European Academy of Dermatology and Venereology, which is that initial 16-week treatment period where patients were given either nemolizumab or the placebo.
This late-breaking presentation examined the 32-week maintenance data from these 2 studies. Patients who are responders by either IGA [Investigator Global Assessment] score or EASI [Eczema Are and Severity Index] 75 response to nemolizumab at week 16, we then re-randomized to get ongoing nemolizumab every 4 weeks, a maintenance dose of every 8 weeks, or placebo at every 4-week intervals for another 32 weeks. And all this is in the background of using topical prescription, topical therapy, corticosteroids, or calcineurin inhibitors.
And what we found was that at week 48, so 32 weeks after that 16-week initial read out, that a very high proportion of patients who are responders maintained that response, really on all doses, whether it was the ongoing every 4-week dose or the every 8-week dose, and even for many who were getting the placebo. And that was true whether it was for IGA responses getting to clear/almost clear, EASI 75 responses, 4-point reduction in itch, as well as even sleep responses and quality of life and things like that. So, we're really seeing good durability of response. Even for some of the end points [there’s] a little bit of an ongoing gain of response beyond week 16 out to that week 48 period.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Alopecia Areata Risk Associated With Atopy, Allergies
May 13th 2024A genetic study suggests people with allergies and eczema are more likely to develop alopecia areata, an autoimmune disease that causes hair loss. Researchers believe this link may be due to similar immune system responses.
Read More
Metabolic Syndrome, Obesity Contribute to Breast Cancer Mortality in Postmenopausal Women
May 13th 2024A large study finds that obesity and metabolic syndrome raise breast cancer mortality risk, but through different mechanisms. Metabolic syndrome is linked to a specific type of breast cancer, whereas obesity increases risk across all breast cancer subtypes.
Read More